Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

121. Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis. Full Text available with Trip Pro

Correlation between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility. A meta-analysis. The aim of this meta-analysis was to undertake a meta-analysis to evaluate the correlation between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene rs221775 A>G single nucleotide polymorphism and the susceptibility of multiple sclerosis (MS) susceptibility.Published manuscripts about CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple (...) sclerosis susceptibility were searched in the computerized bibliographic searches of Pubmed Embase and China National Knowledge Infrastructure (CNKI). Potential studies were screened and data for 5025 MS patients and 4706 controls from 20 publications were included. The association between CTLA-4 gene rs221775A>G single nucleotide polymorphism and multiple sclerosis susceptibility were demonstrated by odds ratio (OR) and 95% confidence interval (95%CI).The pooled results showed no significant

2017 Open medicine (Warsaw, Poland)

122. Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. Full Text available with Trip Pro

Stress and multiple sclerosis: A systematic review considering potential moderating and mediating factors and methods of assessing stress. Research about the effects of stress on multiple sclerosis has yielded contradictory results. This study aims to systematically review the evidence focusing on two possible causes: the role of stress assessment and potential moderating and mediating factors. The Web of Knowledge (MEDLINE and Web of Science), Scopus, and PsycINFO databases were searched (...) for relevant articles published from 1900 through December 2014 using the terms "stress*" AND "multiple sclerosis." Twenty-three articles were included. Studies focused on the effect of stress on multiple sclerosis onset (n = 9) were mostly retrospective, and semi-structured interviews and scales yielded the most consistent associations. Studies focused on multiple sclerosis progression (n = 14) were mostly prospective, and self-reported diaries yielded the most consistent results. The most important

2017 Health psychology open

123. Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. (Abstract)

Living near major roads and the incidence of dementia, Parkinson's disease, and multiple sclerosis: a population-based cohort study. Emerging evidence suggests that living near major roads might adversely affect cognition. However, little is known about its relationship with the incidence of dementia, Parkinson's disease, and multiple sclerosis. We aimed to investigate the association between residential proximity to major roadways and the incidence of these three neurological diseases (...) in Ontario, Canada.In this population-based cohort study, we assembled two population-based cohorts including all adults aged 20-50 years (about 4·4 million; multiple sclerosis cohort) and all adults aged 55-85 years (about 2·2 million; dementia or Parkinson's disease cohort) who resided in Ontario, Canada on April 1, 2001. Eligible patients were free of these neurological diseases, Ontario residents for 5 years or longer, and Canadian-born. We ascertained the individual's proximity to major roadways

2017 Lancet

124. Ocrevus - ocrelizumab - Primary progressive multiple sclerosis

Ocrevus - ocrelizumab - Primary progressive multiple sclerosis ocrelizumab | CADTH.ca Find the information you need ocrelizumab ocrelizumab Last Updated: May 9, 2018 Result type: Reports Project Number: SR0542-000 Product Line: Generic Name: ocrelizumab Brand Name: Ocrevus Manufacturer: Hoffman-La Roche Limited Indications: Primary progressive multiple sclerosis Submission Type: New Indication Project Status: Complete Biosimilar: No Date Recommendation Issued: April 26, 2018 Recommendation Type (...) to applicant and drug plans April 05, 2018 Embargo period ended and validation of redacted CDR review report(s) received April 19, 2018 CDEC Final Recommendation issued to applicant and drug plans April 26, 2018 CDEC Final Recommendation posted April 30, 2018 Final CDR review report(s) and patient input posted May 08, 2018 Tags multiple sclerosis, multiple sclerosis, chronic progressive, multiple sclerosis, relapsing-remitting, Ocrevus; ocrelizumab; PPMS; primary progressive multiple sclerosis Files Follow

2017 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

131. Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis

Ocrelizumab (Ocrevus Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation HAYES, Inc. Ocrelizumab (Ocrevus; Genentech Inc.) for primary progressive and relapsing-remitting multiple sclerosis. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Multiple sclerosis (MS) is an autoimmune disorder that impacts the spinal cord and brain. MS presents in various forms, including relapsing-remitting MS (RRMS) or primary progressive MS (PPMS). Technology Description: Ocrelizumab (Ocrevus) is a humanized monoclonal antibody therapy

2017 Health Technology Assessment (HTA) Database.

132. Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate Article Text Commentary: General medicine Ocrelizumab

2017 Evidence-Based Medicine

133. Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis

Fingolimod (Gilenya) - highly active relapsing remitting multiple sclerosis Final Appraisal Recommendation Advice No: 3516 – December 2016 Fingolimod (Gilenya ® ) 0.5 mg hard capsules Submission by Novartis Pharmaceuticals UK Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3135), which (...) in full and cited as: All Wales Medicines Strategy Group Final Appraisal Recommendation – 3516: Fingolimod (Gilenya ® ) 0.5 mg hard capsules December 2016 Recommendation of AWMSG Fingolimod (Gilenya ® ) is recommended as an option for use within NHS Wales for use as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient group: - patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling

2017 All Wales Medicines Strategy Group

134. 29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Full Text available with Trip Pro

29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has

2016 Electronic physician

135. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. Full Text available with Trip Pro

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B cells.In two identical phase 3 trials, we randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocrelizumab at a dose of 600 mg every 24 weeks or subcutaneous interferon beta-1a at a dose of 44 μg three times weekly for 96 weeks. The primary end (...) to 0.81; P<0.001), as was the percentage of patients with disability progression confirmed at 24 weeks (6.9% vs. 10.5%; hazard ratio, 0.60; 95% CI, 0.43 to 0.84; P=0.003). The mean number of gadolinium-enhancing lesions per T1-weighted magnetic resonance scan was 0.02 with ocrelizumab versus 0.29 with interferon beta-1a in trial 1 (94% lower number of lesions with ocrelizumab, P<0.001) and 0.02 versus 0.42 in trial 2 (95% lower number of lesions, P<0.001). The change in the Multiple Sclerosis

2016 NEJM Controlled trial quality: predicted high

136. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. Full Text available with Trip Pro

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.In this phase 3 trial, we randomly assigned 732 patients with primary progressive multiple sclerosis in a 2:1 ratio to receive intravenous (...) of serious adverse events and serious infections.Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo. Extended observation is required to determine the long-term safety and efficacy of ocrelizumab. (Funded by F. Hoffmann-La Roche; ORATORIO ClinicalTrials.gov number, NCT01194570 .).

2016 NEJM Controlled trial quality: predicted high

137. Effectiveness and user experience of web-based interventions for increasing physical activity in people with multiple sclerosis: a comprehensive systematic review protocol. Full Text available with Trip Pro

Effectiveness and user experience of web-based interventions for increasing physical activity in people with multiple sclerosis: a comprehensive systematic review protocol. The overall aim of this comprehensive systematic review is to explore the use of web-based interventions for increasing physical activity levels in people with a diagnosis of multiple sclerosis (MS).The quantitative objectives are to identify:The qualitative objectives are to.

2016 JBI database of systematic reviews and implementation reports

138. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort

Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal (...) multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort. Health Technology Assessment 2016; 20(81) Authors' objectives The ability to better predict disease progression represents a major unmet need in multiple sclerosis (MS), and would help to inform therapeutic and management choices. This study aims to develop multilevel models using longitudinal data on disease progression in patients with relapsing–remitting MS (RRMS

2016 Health Technology Assessment (HTA) Database.

139. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Full Text available with Trip Pro

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis. Interferons-beta (IFNs-beta) and glatiramer acetate (GA) were the first two disease-modifying therapies (DMTs) approved 20 years ago for the treatment of multiple sclerosis (MS). DMTs' prescription rates as first or switching therapies and their costs have both increased substantially over the past decade. As more DMTs become available, the choice of a specific DMT should reflect the risk/benefit profile (...) acetate for relapsing-remitting multiple sclerosis' (first published in the Cochrane Library 2014, Issue 7).To assess whether IFNs-beta and GA differ in terms of safety and efficacy in the treatment of people with relapsing-remitting (RR) MS.We searched the Trials Register of the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group (08 August 2016) and the reference lists of retrieved articles. We contacted authors and pharmaceutical companies.Randomised controlled trials (RCTs) comparing

2016 Cochrane

140. Diagnosis of multiple sclerosis: progress and challenges. Full Text available with Trip Pro

Diagnosis of multiple sclerosis: progress and challenges. The diagnosis of multiple sclerosis is based on neurological symptoms and signs, alongside evidence of dissemination of CNS lesions in space and time. MRI is often sufficient to confirm the diagnosis when characteristic lesions accompany a typical clinical syndrome, but in some patients, further supportive information is obtained from cerebrospinal fluid examination and neurophysiological testing. Differentiation is important from other (...) diseases in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis) and from non-demyelinating disorders such as chronic small vessel disease and other inflammatory, granulomatous, infective, metabolic, and genetic causes that can mimic multiple sclerosis. Advances in MRI and serological and genetic testing have greatly increased accuracy in distinguishing multiple sclerosis from these disorders, but misdiagnosis can occur. In this Series

2016 Lancet